{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-217822","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.087673+00:00","generated_at":"2026-05-31T05:14:57.861150+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Fulcrum Therapeutics Phase 3 losmapimod trial fails; program suspended","bullets":["REACH trial missed primary endpoint: RSA change p=0.75 vs placebo at week 48.","All secondary endpoints (MFI, shoulder strength, PROs) did not reach statistical significance.","Fulcrum suspends losmapimod development; safety profile consistent with prior studies.","$273.8M cash as of June 30 used for pociredir (SCD), DBA programs, and early discovery."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-217822","json":"https://secwatch.observer/filing/0001193125-24-217822.json","markdown":"https://secwatch.observer/filing/0001193125-24-217822.md","text":"https://secwatch.observer/filing/0001193125-24-217822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524217822/0001193125-24-217822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524217822/d844807d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:14:57.861150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}